Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration.
The pharmacokinetics of cefuroxime were determined in ten patients during intermittent hemofiltration (IHF) and in three patients during continuous arteriovenous hemofiltration (CAVH). All patients received a bolus dose of 1.5 g of cefuroxime intravenously and the concentrations of cefuroxime in serum and ultrafiltrate were followed during the hemofiltration period and up to 16 hours after injection of cefuroxime. During IHF the mean terminal half-life of cefuroxime was 1.6 +/- 0.3 hours compared with a terminal half-life of 21.7 +/- 5 hours after treatment. The total cefuroxime clearance was 120 +/- 22 ml/min. The hemofiltration clearance represented 86% of the total clearance and the hemofiltration process removed in average 63% of the dose. During CAVH the terminal half-life of cefuroxime was 7.9 +/- 2.2 hours. The total plasma clearance for cefuroxime was 32 +/- 7.5 ml/min where the CAVH-treatment represented only 34% of the total clearance. From these data we suggest that a full loading dose (1.5 g of cefuroxime) should be given after each intermittent hemofiltration treatment when performed every second day. In CAVH, where nonrenal clearance will influence the dosage scheme significantly, we suggest an initial dose of 1.5 g of cefuroxime to be followed by a supplementary dose of 750 mg every 20-24 h.
Weiss
L G
LG
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Cars
O
O
Danielson
B G
BG
Grahnen
A
A
Wikström
B
B
D000368:Aged; D002444:Cefuroxime / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002511:Cephalosporins / Q000493:pharmacokinetics*; D006440:Hemofiltration; D006801:Humans; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged
D002511:Cephalosporins; D002444:Cefuroxime